Pay attention to the infectious complications in the clinical application of biological agents
Biological agents have been widely used in the treatment of many clinical diseases by targeting specific immune cells or cytokines. In the course of clinical use, biological agents can lead to secondary immune deficiency, which increases the risk of infection. At present, there are no evidence-based guidelines or management opinions on the differences of infections caused by various biological agents, how to identify infectious complications in the course of treatment with different biological agents at an early stage, and how to take effective and targeted prevention. This paper summarizes the infection complications and their characteristics that need to be paid attention to in the clinical introduction of biological agents, aiming to help clinicians make reasonable decisions for infection complications in the process of using biological agents, reduce the incidence of infection, and improve the success rate of diagnosis and treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
|---|---|
| Enthalten in: |
Zhonghua yi xue za zhi - 103(2023), 33 vom: 05. Sept., Seite 2546-2551 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Ma, X J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 01.09.2023 Date Revised 01.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3760/cma.j.cn112137-20230608-00962 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361480571 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361480571 | ||
| 003 | DE-627 | ||
| 005 | 20231226085228.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3760/cma.j.cn112137-20230608-00962 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361480571 | ||
| 035 | |a (NLM)37650201 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Ma, X J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pay attention to the infectious complications in the clinical application of biological agents |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.09.2023 | ||
| 500 | |a Date Revised 01.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Biological agents have been widely used in the treatment of many clinical diseases by targeting specific immune cells or cytokines. In the course of clinical use, biological agents can lead to secondary immune deficiency, which increases the risk of infection. At present, there are no evidence-based guidelines or management opinions on the differences of infections caused by various biological agents, how to identify infectious complications in the course of treatment with different biological agents at an early stage, and how to take effective and targeted prevention. This paper summarizes the infection complications and their characteristics that need to be paid attention to in the clinical introduction of biological agents, aiming to help clinicians make reasonable decisions for infection complications in the process of using biological agents, reduce the incidence of infection, and improve the success rate of diagnosis and treatment | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Biological Factors |2 NLM | |
| 700 | 1 | |a Liu, X |e verfasserin |4 aut | |
| 700 | 1 | |a Ge, Y |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua yi xue za zhi |d 1994 |g 103(2023), 33 vom: 05. Sept., Seite 2546-2551 |w (DE-627)NLM000566861 |x 0376-2491 |7 nnns |
| 773 | 1 | 8 | |g volume:103 |g year:2023 |g number:33 |g day:05 |g month:09 |g pages:2546-2551 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3760/cma.j.cn112137-20230608-00962 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 103 |j 2023 |e 33 |b 05 |c 09 |h 2546-2551 | ||